Stability and Degradation Kinetic study of Bilastine in Solution State by RP-HPLC Method
Abstract
Aim: The current study dealt with the degradation behavior of Bilastine and degradation kinetics of a drug in solution state. Background: Very limited information on the effect of pH on maximum stability has been published. In order to understand the degradation kinetics of bilastine, aqueous stability studies were carried out, because such studies on bilastine have not been reported in the literature, further no methods have reported about shelf-life determination of bilastine. The study design involves selection of stability indicating RP-HPLC method for estimation of drug then evaluation of degradation kinetics, shelf-life determination and validation of proposed method. Results: The Shimadzu HPLC series 1100 was used for stress degradation analysis of bilastine in tablet dosage form. The analysis was performed using Agilent ZORBAX SB-C8 (4.6×150×5µm) column and Phosphate Buffer: Acetonitrile (pH-5.0) in the ratio of 60:40 as mobile phase; wavelength selected for analysis was 254nm with the flow rate of 1mL/min at which drug showed sharp peak. The analysis was performed on the isocratic pump mode with the injection volume of 20µl. The mobile phase is used as diluent. The proposed method was found to be linear over the range 10 to 50 µg/mL. The analysis was performed by placing standard and samples with 7 different pH buffer, oxidative and neutral hydrolytic solutions in oven at 40ºC, 60⁰C and room temperature for an interval of 30, 60, 90, 120, 150, 180 mints for standard and samples. The results indicated that the pH, temperature, ionic strength and oxidation greatly influence the stability of Bilastine and the degradation behavior of Bilastine followed pseudo-first-order kinetics. Bilastine was most stable in neutral, alkaline, lower temperature conditions and lower ionic strength. Conclusion: The proposed method was found to be specific, selective and robust and successfully applied for its assay, degradation (stress testing) of drug and degradation kinetics in solution state.
Keywords: Degradation, Stability, Bilastine, RP-HPLC, Kinetics
Keywords:
Degradation, Stability, Bilastine, RP-HPLC, KineticsDOI
https://doi.org/10.22270/jddt.v11i5-S.5086References
Pokharana M, Vaishnav R, Goyal A, Shrivastava A. Stability Testing Guidelines of Pharmaceutical Products, Journal of Drug Del & Therapeutics, 2018; 8:169-175. https://doi.org/10.22270/jddt.v8i2.1564
Ahuja S. and M. Dong, 1st ed Handbook of Pharmaceutical analysis. Separation Science and Technology, 2005; 6:336-337. https://doi.org/10.1016/S0149-6395(05)80045-5
Panda A, Kulkarni S, Tiwari R, Stability Studies: An Integral Part of Drug Development Process, Int Jr of Pharm Res and Bio-Sci. 2013; 2:69-80.
FDA, International Conference on Harmonization: Stability Testing of New Drug Substance and Product. Federal Register (ICH Q1A), 1994; 59(183):48753-48759.
Available at: http://www.wikipedia.org/wiki/Bilastine (Accessed 15 July 2020)
Available at: http://www.drugbank.ca/drug/Bilastine (Accessed 15 July 2020)
Available at: http://www.ChemSpider.com (Accessed 15 July 2020)
Togawa M, Yamaya H, Rodrıguez M, Nagashima H, Pharmacokinetics, Pharmacodynamics and Population Pharmacokinetic/Pharmacodynamic Modelling of Bilastine, a Second-Generation Antihistamine, in Healthy Japanese Subjects, Clin Drug Investigation, 2016; 36:1011–1021. https://doi.org/10.1007/s40261-016-0447-2
Wolthers O D, Bilastine: A New Nonsedating Oral H1 Antihistamine for Treatment of Allergic Rhinoconjunctivitis and Urticaria, BioMed Research International, 2013; 1-6. https://doi.org/10.1155/2013/626837
Leceta A, Sologuren A, Valiente R, Campo C, Labeaga L, Bilastine in Allergic Rhinoconjunctivitis and Urticaria: A Practical Approach to Treatment Decisions Based on Queries Received by the Medical Information Department, Drugs in Context, 2017; 6:212500. https://doi.org/10.7573/dic.212500
Published
Abstract Display: 1601 
PDF Downloads: 1475 PDF Downloads: 372 How to Cite
Issue
Section
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
How to Cite
.